Regeneron sues Sandoz to halt biosimilar to its blockbuster eye drug

Regeneron is going after Sandoz in a New Jersey federal court over Sandoz’s recently-approved drug Enzeevu, a biosimilar to Regeneron’s blockbuster eye treatment Eylea. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

30 years for a bio-based future – Biotech Investments

EQS-News: BRAIN Biotech AG / Key word(s): Miscellaneous Anniversary of BRAIN Biotech AG: 30 years for a bio-based future 19.06.2023 / 12:30 CET/CEST The issuer

June 20, 2023

Federal nutrition initiative can offer infant feeding support and counseling to disabled parents

Infant feeding, involving breastfeeding, formula feeding, and the introduction of solid foods, is crucial for parenting.

June 19, 2024

MSD snags European approval for pulmonary arterial hypertension therapy – Pharmaceutical Technology

MSD’s Winrevair has been approved to treat pulmonary arterial hypertension (PAH), a disorder which is caused by high blood pressure in the lungs. Credits: MMD

August 26, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.